Related Experiment Video
Updated: Aug 30, 2025
05:54
Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
Published on: January 24, 2025
401
Weight Reduction as an Adjunctive Management Strategy for Diabetic Retinopathy
1John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Missouri Medicine
|August 29, 2022
Summary
Weight reduction may help preserve vision in patients with diabetic retinopathy unresponsive to standard treatments. This approach could supplement current ophthalmic care for diabetes-related vision loss.
Area of Science:
- Ophthalmology
- Endocrinology
- Metabolic Diseases
Background:
- Global rates of obesity and diabetes are rising, increasing the incidence of diabetic retinopathy.
- Diabetic retinopathy is a leading cause of visual impairment.
- Current therapies for diabetic retinopathy are not effective for all patients.
Purpose of the Study:
- To explore the potential of weight reduction strategies as adjunctive therapy for diabetic retinopathy.
- To assess the role of weight management in preserving vision for patients with diabetes.
Main Methods:
- Review of current evidence on obesity, diabetes, and diabetic retinopathy treatments.
- Analysis of studies investigating the impact of weight reduction on ophthalmic health in diabetic patients.
Main Results:
- Weight reduction strategies show promise as supplementary treatments for diabetic retinopathy.
- Evidence suggests that managing obesity can positively impact vision preservation in diabetic individuals.
Conclusions:
- Weight reduction interventions may offer significant benefits as adjunctive therapy for diabetic retinopathy.
- Integrating weight management into care plans could improve visual outcomes for diabetic patients with retinopathy.
More Related Videos
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
342
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
342
01:26Atherosclerosis III: Management
26
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
26
01:22Diabetes Mellitus: Type 2 and Gestational
2.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.7K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
272
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
272
01:16Insulin: Dosing Regimen and Adverse Effects
235
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
235
01:26Nephrotic Syndrome II : Assessment and Medical Management
18
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
18